Surgeries & Interventions August 28, 2023
ReCor Medical Takes Renal Denervation Lead Following FDA Panel Review August 28, 2023
The renal denervation votes are in, and they’re pointing in very different directions for ReCor Medical and Medtronic’s respective RDN devices. The companies argued their premarket approval cases to an FDA expert panel last week, and only ReCor walked away with panel support.
Cardiology Testing August 24, 2023
Simplifying CVD and Renal Assessments with Multimarker Blood Testing August 24, 2023
Blood biomarker tests play a key role in assessing cardiovascular and renal risks in diabetic patients, but a recent AHA study out of Harvard Medical School suggests that a “simple” new multimarker test could significantly improve these assessments and downstream treatment decisions.
Cardiology Guidelines August 21, 2023
HFrEF Treatment’s Guideline Barrier August 21, 2023
Guideline-directed medical therapies (GDMT) for heart failure have proven to be “profoundly effective at reducing morbidity and mortality,” and yet prescription rates for many HFrEF therapies are far too low and inconsistent. To unravel this challenge, a UCLA team analyzed VA data from 178k veterans in 306 Hospital Referral Regions (HRRs) across the US.
Electrophysiology August 17, 2023
Questioning the Cath Lab for Arrhythmia Risk Management August 17, 2023
Many arrhythmia patients take a trip to the cath lab before they end up in the EP lab, but a pair of new studies suggest that many of these “risk management” cath lab procedures are unnecessary - and might even increase risks.
Pharmaceuticals August 14, 2023
Novo Nordisk Expands Weight Loss Pipeline with Inversago Acquisition August 14, 2023
Novo Nordisk added to its leadership position in the white hot weight loss segment, acquiring Canadian biotech Inversago Pharma for up to $1.075 billion depending on certain development and commercial milestones.
Pharmaceuticals August 10, 2023
Wegovy Cuts Weight and Cardiovascular Events August 10, 2023
The hottest medication in the world got even hotter this week after Novo Nordisk revealed that its weight loss drug Wegovy (semaglutide) also reduces major cardiac event risks by 20% - a revelation that could change how GLP-1s are used, perceived, and reimbursed.
Pharmaceuticals August 7, 2023
Novartis and Ionis Double Down on Lp(a) August 7, 2023
Novartis and Ionis Pharmaceuticals doubled down on their Lp(a) alliance, launching a second collaboration focused on developing and commercializing a treatment for patients with lipoprotein(a)-driven cardiovascular disease.
Digital Health August 3, 2023
Hims’ Dual-Action Cardiovascular Health Expansion August 3, 2023
Massive direct-to-consumer health and wellness company, Hims & Hers, announced an unexpected expansion into cardiovascular care last week with the launch of Heart Health by Hims.
Cardiology Pharmaceuticals July 31, 2023
Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4 July 31, 2023
Results from Eli Lilly’s SURMOUNT-3 and SURMOUNT-4 trials are in, and they confirmed that its GLP-1 / GIP agonist tirzepatide (aka Mounjaro) drives significant weight loss among obese or overweight adults who don’t have type 2 diabetes.
Cardiology Pharmaceuticals July 27, 2023
Alnylam and Roche’s Long-Lasting Antihypertensive Alliance July 27, 2023
Just days after Alnylam Pharmaceuticals showed that a single injection of zilebesiran can control blood pressure for up to six months, the biotech has joined forces with Roche to usher the mid-stage medication through its clinical trials into clinical use.
Cardiology Pharmaceuticals July 24, 2023
Zilebesiran’s Long-Lasting Antihypertensive Potential July 24, 2023
Could the first long-lasting antihypertensive medication be on the way? Results of a Phase 1 study in NEJM suggests that Alnylam Pharmaceuticals’ zilebesiran is a frontrunner to become that drug, showing that a single injection controls blood pressure for up to six months.
Digital Health July 20, 2023
Astellas Expands into Heart Failure Digital Therapeutics July 20, 2023
Astellas Pharma and Eko Health announced an alliance that will make Eko's digital stethoscope and CVD detection software and Welldoc’s chronic care management capabilities the core components of Astellas’ new Z1608 digital therapeutic for heart failure.
Cardiology Pharmaceuticals July 17, 2023
Lilly Diversifies Weight Loss Pipeline with Versanis Acquisition July 17, 2023
Eli Lilly bolstered its already strong position in the white hot obesity drug segment, acquiring cardiometabolic disease biopharma startup Versanis for up to $1.92 billion.
Cardiology Pharmaceuticals July 13, 2023
Cholesterol Control Falls Short in CAD Patients July 13, 2023
For years we’ve known that controlling LDL cholesterol lowers the risk of future cardiovascular events in people with coronary artery disease. And yet, a new JAMA paper reveals that most CAD patients fail to meet recommended cholesterol targets, and many of them still aren't taking LDL-lowering medications.
Surgeries & Interventions July 10, 2023
The First Dissolvable Heart Monitor and Pacer July 10, 2023
A team of Northwestern and George Washington scientists took a big step towards revolutionizing how patients are monitored and treated after major cardiac events, unveiling the first dissolvable cardiac mapping and pacing device.
Artificial Intelligence July 6, 2023
Improving Occlusion MI Detection with ECG AI July 6, 2023
A University of Pittsburgh-led team developed an ECG-based AI model capable of detecting occlusion myocardial infarction, showing that it improves both OMI detection and assessments, and finding that it has real clinical potential.
Cardiology Pharmaceuticals June 29, 2023
Two Sides to Bempedoic Acid’s Primary Prevention Impact June 29, 2023
A Cleveland Clinic-led study stunned the ADA 2023 crowd this week, showing that bempedoic acid (Esperion’s Nexletol) significantly reduced future cardiovascular events among people with high CVD risks who had never experienced a major cardiac event.
Surgeries & Interventions June 26, 2023
How to Assess the Abiomed Impella Pump June 26, 2023
Abiomed’s Impella pump is being used across America to support patients with acute myocardial infarction with cardiogenic shock (AMICS) - but do we know it’s safe and effective?
Cardiology Pharmaceuticals June 22, 2023
Agepha’s Lodoco FDA-Approved for CVD Inflammation June 22, 2023
Agepha Pharma’s Lodoco (colchicine) just became the first anti-inflammatory drug to land FDA approval for reducing cardiovascular event risks, marking a major milestone in the emerging field of CVD inflammation treatment.
